Appeals court upholds dismissal of vaccine suit

Sep 29, 2009 By NEDRA PICKLER , Associated Press Writer

(AP) -- A federal appeals court on Tuesday upheld a program that requires some members of the military to be vaccinated against anthrax over objections from service members who say the vaccine has not been proven to be effective.

The U.S. Court of Appeals in Washington upheld a lower court's decision dismissing a case brought by eight service members who challenged the Food and Drug Administration's determination that the vaccine was effective.

The plaintiffs also wanted to stop the Defense Department's requirement that service members at risk for anthrax exposure must be vaccinated.

Anthrax is a bacterial disease caused by infection with spores that mainly affects animals but that humans can contract through skin contact, inhalation and ingestion. Inhaled anthrax is more difficult to treat and can be fatal.

The military's vaccine, produced by Michigan-based Bioport Corp., was approved based on a human test in the 1950s that studied textile workers at risk for the disease because they routinely handled infected imported goat hair. Since then industrial conditions have improved and there has not been another study because of the associated with exposing people to the spores.

The service members argued that because the one human study included only a few inhalation cases, there is insufficient evidence to conclude the vaccine is effective against them.

But the appeals court ruled that the service members who filed the suit did not provide any scientific evidence to prove the was ineffective. "We are presented with a scientific judgment by the FDA to which we owe considerable deference," the court found.

John J. Michels Jr., attorney for the service members, said the case shows how difficult it is to challenge a ruling by a federal agency. He said they had not decided whether to appeal the case further.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: FDA OKs Cubist antibiotic for serious infections

add to favorites email to friend print save as pdf

Related Stories

Court Denies Vonage Bid for Patent Case Retrial

May 04, 2007

A U.S. appeals court denies a request by Internet phone company Vonage Holdings that it order a retrial in the patent infringement case brought against it by Verizon Communications.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.